Workflow
Tai Ping Yang
icon
Search documents
出版24H1总结:所得税致净利润承压,中期分红稳定全年预期
Tai Ping Yang· 2024-09-10 01:30
[Table_Message] 2024-09-08 行业周报 看好/维持 传媒互联网 行 业 研 究 报 告 [Table_Title] 传媒互联网 出版 24H1 总结:所得税致净利润承压,中期分红稳定全年预期 (2024.09.02-09.08) ◼ 走势对比 ◼ 子行业评级 ◼ 相关研究报告 《7 月游戏市场收入 278 亿,OpenAI 草 莓模型有望年内上线》 《<黑神话:悟空>销量突破 1000 万套, 有望提升板块关注度》 ◼ 证券分析师:郑磊 E-MAIL:zhenglei@tpyzq.com 执业资格证书编码:S1190523060001 [Table_Summary] 报告摘要 ➢ 所得税优惠政策到期致使出版公司净利润承压 2024H1 中信行业分类中的 31 家出版公司共 16 家实现营收同比增 长,其中山东出版以 13.77%的增幅位列第一,主要系教材、教辅等 收入增加。而因经营性文化事业单位转制政策的所得税优惠政策到 期,出版公司所得税费用普遍出现大幅增长。受此影响,仅 10 家公 司实现归母净利润同比增长。总体来看,2024H1 受图书销售市场、 平台电商和实体店渠道负增长,所得 ...
农林牧渔周报(第36期):猪价持续高位运行,粮价有望底部反转
Tai Ping Yang· 2024-09-10 01:30
农林牧渔 行 业 研 究 报 告 行业周报 看好/维持 [Table_Message]2024-09-08 [Table_Title] 农林牧渔 周报(第 36 期):猪价持续高位运行,粮价有望底部反转 ◼ 走势对比 (20%) (14%) (8%) (2%) 3% 9% 22/12/2623/2/2623/4/2623/6/2623/8/2623/10/26 农林牧渔 沪深300 | --- | --- | |--------------------------------------------------------|-------| | 动物保健Ⅱ 看好 \n[Table_IndustryList] ◼ 子行业评级 | | | 饲料 看好 | | | 养殖业 看好 | | | 种植业 看好 | | | [Table_Company ◼ 推荐公司及评级 Info] | | | 天康生物 (002100) | 买入 | | 科前生物 (688526) | 买入 | | 唐人神 (002567) | 买入 | [Table_ReportInfo] 相关研究报告: 《周报(第 33 期):养殖盈利高涨, 重视 ...
有色金属行业周报:降息周期即将开启,基本金属供需偏紧
Tai Ping Yang· 2024-09-10 01:01
2024 年 09 月 08 日 行业周报 看好/维持 有色金属 有色金属 降息周期即将开启,基本金属供需偏紧(20240902-20240906) ◼ 走势比较 (30%) (20%) (10%) 0% 10% 20% 23/9/8 23/11/1924/1/3024/4/1124/6/2224/9/2 有色金属 沪深300 相关研究报告 <<【太平洋有色】有色金属行业周报 (20240826-20240830):9 月降息愈 发明确,贵金属价格维持强势>>-- 2024-09-03 <<【太平洋有色】有色金属行业周报 (20240825):软着陆预期增强,商品 价格继续回升>>--2024-08-26 <<【太平洋有色】洛阳钼业 2024 年 中报业绩预告点评:五年目标取得开 门红,向全球一流矿企迈进>>-- 2024-08-21 证券分析师:刘强 电话: E-MAIL:liuqiang@tpyzq.com 分析师登记编号:S1190522080001 证券分析师:梁必果 电话: E-MAIL:liangbg@tpyzq.com 分析师登记编号:S1190524010001 研究助理:钟欣材 电话: E- ...
汽车行业周报:特斯拉FSD入华
Tai Ping Yang· 2024-09-10 01:01
行 业 研 究 2024 年 09 月 09 日 行业周报 看好/维持 汽车 汽车 特斯拉 FSD 入华 ◼ 走势比较 (30%) (20%) (10%) 0% 10% 20% 23/9/8 23/11/1924/1/3024/4/1124/6/2224/9/2 汽车 沪深300 ◼ 子行业评级 ◼ 推荐公司及评级 相关研究报告 证券分析师:刘虹辰 电话:010-88321818 E-MAIL:liuhc@tpyzq.com 分析师登记编号:S1190524010002 报告摘要 FSD V12.5.2 将成为 Robotaxi 发布之前最重要的更新,V13 特斯拉 FSD 入华。近日,特斯拉 AI 团队发布 FSD 路线图,9 月推送 V12.5.2 版本,接 管率提升 3 倍,该版本适配 HW3.0 平台,实现与 4.0 平台统一模型;推送 真·智能召唤功能(ASS);推送 Cybertruck 自动泊车;注意力检测支持佩戴 太阳墨镜;高速公路和城市统一技术栈,全部基于端到端;推送 Cyberturuck 的 FSD 功能;10 月将推送 FSD 倒车和车位-车位能力,同时 V13 版本平均接 管率再提升 ...
电力设备及新能源行业新能源周报(第103期):重视结构性向好机会,新市场是核心
Tai Ping Yang· 2024-09-10 01:01
2024 年 09 月 09 日 行业周报 看好/维持 电力设备及新能源 电力设备及新能源 新能源周报(第 103 期):重视结构性向好机会,新市场是核心 (2024/9/2-2024/9/8) ◼ 走势比较 报告摘要 (30%) (24%) (18%) (12%) (6%) 0% 23/9/11 23/11/2224/2/224/4/1424/6/2524/9/5 电力设备及新能源 沪深300 ◼ 子行业评级 | --- | --- | |---------------------|--------------------------------------------| | | | | | | | 电气设备 | 电站设备Ⅱ 无评级 无评级 电源设备 无评级 | | 新 能 源 动 力 系统 | 无评级 | ◼ 推荐公司及评级 相关研究报告 <<远东股份 2024 年半年报点评:收 入稳健增长,海缆工厂即将投产>>-- 2024-09-08 <<天赐材料 2024 半年报点评:锂盐 外售提升市占率,一体化能力持续提 升>>--2024-09-05 <<【太平洋新能源】横店东磁 2024 年 中报点评:印尼光 ...
纳睿雷达:新签合同快速增长,市场领域不断拓展
Tai Ping Yang· 2024-09-10 01:00
Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [7]. Core Insights - The company has experienced rapid growth in new contracts, with a total contract amount of approximately 540 million yuan signed during the reporting period, primarily in May and June. This is expected to lead to a recovery in performance in the fourth quarter as product deliveries and project payments peak [2][3]. - The company reported a revenue of 73 million yuan for the first half of 2024, a year-on-year increase of 0.84%, while net profit attributable to shareholders decreased by 69.60% to 6 million yuan due to increased R&D expenses, bad debt provisions, and charitable donations [2][3]. - The company has expanded its market presence beyond meteorological detection, achieving sales in the flood control sector and launching new products, including a Ku-band dual-polarization active phased array radar [2][3]. Financial Performance - For the first half of 2024, the company achieved a revenue of 73 million yuan, with a net profit of 6 million yuan and basic earnings per share (EPS) of 0.03 yuan, reflecting a decline of 76.92% year-on-year [2][3]. - The company invested 37 million yuan in R&D during the reporting period, a 29.62% increase from the previous year, and obtained several new patents and software copyrights [3]. - The projected net profits for 2024, 2025, and 2026 are estimated at 210 million yuan, 365 million yuan, and 504 million yuan, respectively, with corresponding EPS of 0.97 yuan, 1.68 yuan, and 2.33 yuan [4][3]. Market Expansion - The company has signed cooperation agreements with multiple air traffic control bureaus for trial testing, indicating ongoing efforts to expand its market reach [2][3]. - The introduction of new products and technologies, such as the full-polarization digital active phased array radar, is expected to enhance the company's product line and application scenarios in low-altitude economies [2][3].
赛意信息:毛利率持续提升,积极发力AI
Tai Ping Yang· 2024-09-10 01:00
2024 年 09 月 09 日 公司点评 买入/维持 赛意信息(300687) 目标价: 昨收盘:12.54 毛利率持续提升,积极发力 AI ◼ 走势比较 (60%) (44%) (28%) (12%) 4% 20% 23/9/8 23/11/1924/1/3024/4/1124/6/2224/9/2 赛意信息 沪深300 ◼ 股票数据 总股本/流通(亿股) 4.1/3.3 总市值/流通(亿元) 51.43/40.80 12 个月内最高/最低价 (元) 27.63/11.47 相关研究报告 <<业绩符合预期,智能制造引领>>-- 2024-04-28 <>--2023-11- 01 <<业绩短期承压,泛 ERP 业务有望突 破>>--2023-08-31 事件:公司发布 2024 年半年报。2024 上半年,公司实现营业收入 10.71 亿元,同比增长 1.33%;实现归母净利润 2970.92 万元,同比增长 34.18%;实现扣非归母净利润 2528.78 万元,同比增长 105.76%。 受下游景气度影响收入短期承压。分季度看,公司 24Q2 单季度营收 5.31 亿元,yoy-1.71%;归母净利润 ...
宏信建发2024年半年报点评:业绩增长显著,海外布局加速
Tai Ping Yang· 2024-09-09 04:07
Investment Rating - The report maintains a "Buy" rating for Hongxin Construction Development (09930) [2][3] Core Views - Hongxin Construction Development achieved significant revenue and profit growth in H1 2024, with revenue increasing by 15.8% YoY to RMB 4.87 billion and net profit rising by 13.1% YoY to RMB 270 million [2] - The company's non-asset-driven businesses, particularly engineering technical services and asset management, were the main growth drivers [2] - Overseas market expansion is accelerating, with H1 2024 overseas revenue reaching RMB 73 million, a 62% YoY increase [2] Financial Performance - Revenue breakdown by segment: - Operating lease services: RMB 1.9 billion, down 24.3% YoY [2] - Engineering technical services: RMB 1.95 billion, up 70.6% YoY [2] - Asset management and other services: RMB 1.03 billion, up 84.1% YoY [2] - Gross margins: - Operating lease services: 37.1%, down 2.4 percentage points YoY [2] - Engineering technical services: 27.0%, up 6.3 percentage points YoY [2] - Asset management and other services: RMB 330 million, up 58.0% YoY [2] Equipment Management - Equipment management scale as of H1 2024: - Aerial work platforms: 205,000 units, up 28.1% YoY [2] - New support systems: 1.613 million tons, up 4.0% YoY [2] - New formwork systems: 748,000 tons, up 14.9% YoY [2] - Rental rates: - Aerial work platforms: 65.6%, down 7.9 percentage points YoY [2] - New support systems: 66.9%, up 1.9 percentage points YoY [2] - New formwork systems: 75.6%, up 5.7 percentage points YoY [2] Overseas Expansion - Number of overseas business outlets increased to 35 as of H1 2024, up from 4 at the end of 2023 [2] - Key markets include Malaysia, Vietnam, Indonesia, Thailand, Saudi Arabia, UAE, and Turkey [2] Future Projections - Revenue forecasts: - 2024: RMB 11.21 billion [2][3] - 2025: RMB 12.90 billion [2][3] - 2026: RMB 14.90 billion [2][3] - Net profit forecasts: - 2024: RMB 1.09 billion [2][3] - 2025: RMB 1.22 billion [2][3] - 2026: RMB 1.40 billion [2][3] - PE ratios: - 2024: 3.62x [2][3] - 2025: 3.24x [2][3] - 2026: 2.82x [2][3] Stock Data - Total shares outstanding: 3.197 billion [1] - Market capitalization: HKD 43.48 billion [1] - 12-month high/low: HKD 4.93/HKD 0.91 [1]
医药行业周报:安进1类新药在华再获批临床
Tai Ping Yang· 2024-09-09 03:26
行 业 研 究 医药 安进 1 类新药在华再获批临床 ◼ 走势比较 报告摘要 (30%) (22%) (14%) (6%) 2% 10% 23/9/4 23/11/1624/1/2824/4/1024/6/2224/9/3 医药 沪深300 ◼ 子行业评级 | --- | --- | |-------|-------| | | | | | | ◼ 推荐公司及评级 相关研究报告 <<礼来肾病 1 类新药在中国获批临 床>>--2024-09-04 <<迈瑞医疗点评报告:IVD 和国际业 务增长强劲,"三瑞"数智化建设稳步 推进>>--2024-09-04 证券分析师:周豫 电话: E-MAIL:zhouyua@tpyzq.com 分析师登记编号:S1190523060002 证券分析师:张崴 电话: E-MAIL:zhangwei@tpyzq.com 分析师登记编号:S1190524060001 市场表现: 2024年9月4日,医药板块涨跌幅+0.16%,跑赢沪深300指数0.81pct, 涨跌幅居申万 31 个子行业第 3 名。各医药子行业中,线下药店(+4.71%)、 医药流通(+1.63%)、医疗研发外包 ...
医药行业周报:武田1类创新药拟纳入突破性治疗品种
Tai Ping Yang· 2024-09-09 03:26
2024 年 09 月 06 日 行业周报 看好/维持 医药 行 业 研 究 医药 武田 1 类创新药拟纳入突破性治疗品种 ◼ 走势比较 报告摘要 (20%) (12%) (4%) 4% 12% 20% 23/9/6 23/11/1824/1/3024/4/1224/6/2424/9/5 医药 沪深300 ◼ 子行业评级 | --- | --- | |-------|-------| | | | | | | ◼ 推荐公司及评级 相关研究报告 <<诺华Iptacopan新适应症在华获批 上市>>--2024-09-06 <<礼来肾病 1 类新药在中国获批临 床>>--2024-09-04 证券分析师:周豫 电话: E-MAIL:zhouyua@tpyzq.com 分析师登记编号:S1190523060002 证券分析师:张崴 电话: E-MAIL:zhangwei@tpyzq.com 分析师登记编号:S1190524060001 市场表现: 2024年9月6日,医药板块涨跌幅-1.93%,跑输沪深300指数1.12pct, 涨跌幅居申万 31 个子行业第 27 名。各医药子行业中,线下药店(-1.26%)、 血 ...